Cytomx Therapeutics Share Price Today
(NASDAQ: CTMX)

Name: Cytomx Therapeutics Share Price Today (NASDAQ: CTMX) - Cytomx Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Cytomx Therapeutics share price is $0.86 & ₹74.90 as on 5 Feb 2025, 2.30 'hrs' IST

$0.86

▲

0.02

(2.83%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Cytomx Therapeutics share price in Dollar and Rupees. Guide to invest in Cytomx Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cytomx Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Cytomx Therapeutics share price movements

Today's Low: $0.83
Today's High: $0.88
$0.86
3.49%
Downside
Day's Volatility :5.68%
Upside
2.27%
52 Weeks Low: $0.79
52 Weeks High: $5.85
$0.86
8.14%
Downside
52 Weeks Volatility :86.5%
Upside
85.3%

Cytomx Therapeutics (CTMX) Returns

Period	Cytomx Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-15.99%	0.5%	0.0%
6 Months	-27.58%	-2.3%	0.0%
1 Year	-42.46%	3.8%	0.0%
3 Years	-80.82%	11.4%	-11.7%

Cytomx Therapeutics (CTMX) Key Statistics

in dollars & INR

Previous Close	$0.8401
Open	$0.85
Today's High	$0.88
Today's Low	$0.83
Market Capitalization	$66.5M
Today's Volume	$654.8K
52 Week High	$5.85
52 Week Low	$0.79
Revenue TTM	$126.6M
EBITDA	$8.6M
Earnings Per Share (EPS)	$0.16
PE Ratio	5.31
Profit Margin	10.92%
Quarterly Earnings Growth YOY	0.82%
Return On Equity TTM	-5475.03%

How to invest in Cytomx Therapeutics Stock (CTMX) from India?

It is very easy for Indian residents to invest directly in Cytomx Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cytomx Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cytomx Therapeutics or CTMX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cytomx Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cytomx Therapeutics shares which would translate to 1.013 fractional shares of Cytomx Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cytomx Therapeutics, in just a few clicks!

Returns in Cytomx Therapeutics (CTMX) for Indian investors in Rupees

The Cytomx Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Cytomx Therapeutics investment value today

Current value as on today

₹63,769

Returns

₹36,231

(-36.23%)

Returns from Cytomx Therapeutics Stock

₹41,096 (-41.1%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Cytomx Therapeutics (CTMX)

-73%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Cytomx Therapeutics Stock from India on INDmoney has decreased by -73% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cytomx Therapeutics

TANG CAPITAL MANAGEMENT LLC
9.98%
Bvf Inc
6.68%
Vanguard Group Inc
6.60%
HHG PLC
6.15%
Prosight Management, LP
3.86%
Adage Capital Partners Gp LLC
3.83%

Analyst Recommendation on Cytomx Therapeutics

Hold

46%Buy

53%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Cytomx Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cytomx Therapeutics Stock (CTMX)

What analysts predicted

Upside of 444.88%

Target:

$4.69

Current:

$0.86

Insights on Cytomx Therapeutics Stock (Ticker Symbol: CTMX)

Price Movement
In the last 1 month, CTMX stock has moved down by -25.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 25.11M → 33.43M (in $), with an average increase of 24.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -6.53M → 5.73M (in $), with an average increase of 213.9% per quarter
CTMX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 101.8%
CTMX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 169.1%
Price to Sales
ForCTMX every $1 of sales, investors are willing to pay $0.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

CTMX Cytomx Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$59.5M	↓ 16.92%
Net Income	$-84.6M	↑ 96.3%
Net Profit Margin	-142.19%	↓ 82.02%

	FY19	Y/Y Change
Revenue	$57.5M	↓ 3.38%
Net Income	$-102.2M	↑ 20.84%
Net Profit Margin	-177.84%	↓ 35.65%

	FY20	Y/Y Change
Revenue	$100.4M	↑ 74.58%
Net Income	$-32.9M	↓ 67.83%
Net Profit Margin	-32.77%	↑ 145.07%

	FY21	Y/Y Change
Revenue	$69.6M	↓ 30.68%
Net Income	$-80.6M	↑ 145.24%
Net Profit Margin	-115.92%	↓ 83.15%

	FY22	Y/Y Change
Revenue	$53.2M	↓ 23.59%
Net Income	$-97.3M	↑ 20.65%
Net Profit Margin	-183.02%	↓ 67.1%

	FY23	Y/Y Change
Revenue	$101.2M	↑ 90.38%
Net Income	$-569.0K	↓ 99.42%
Net Profit Margin	-0.56%	↑ 182.46%

	Q2 FY23	Q/Q Change
Revenue	$24.7M	↑ 5.21%
Net Income	$-1.1M	↑ 12.18%
Net Profit Margin	-4.4%	↓ 0.28%

	Q3 FY23	Q/Q Change
Revenue	$26.4M	↑ 6.71%
Net Income	$3.0M	↓ 375.25%
Net Profit Margin	11.34%	↑ 15.74%

	Q4 FY23	Q/Q Change
Revenue	$26.6M	↑ 0.85%
Net Income	$837.0K	↓ 72.03%
Net Profit Margin	3.15%	↓ 8.19%

	Q1 FY24	Q/Q Change
Revenue	$41.5M	↑ 55.83%
Net Income	$13.8M	↑ 1547.67%
Net Profit Margin	33.26%	↑ 30.11%

	Q2 FY24	Q/Q Change
Revenue	$25.1M	↓ 39.43%
Net Income	$-6.5M	↓ 147.38%
Net Profit Margin	-26.02%	↓ 59.28%

	Q3 FY24	Q/Q Change
Revenue	$33.4M	↑ 33.12%
Net Income	$5.7M	↓ 187.79%
Net Profit Margin	17.16%	↑ 43.18%

	FY18	Y/Y Change
Profit	$59.5M	↓ 16.92%

	FY19	Y/Y Change
Profit	$57.5M	↓ 3.38%

	FY20	Y/Y Change
Profit	$100.4M	↑ 74.58%

	FY21	Y/Y Change
Profit	$69.6M	↓ 30.68%

	FY22	Y/Y Change
Profit	$53.2M	↓ 23.59%

	FY23	Y/Y Change
Profit	$101.2M	↑ 90.38%

	Q2 FY23	Q/Q Change
Profit	$23.2M	↑ 5.4%

	Q3 FY23	Q/Q Change
Profit	$25.0M	↑ 7.61%

	Q4 FY23	Q/Q Change
Profit	$26.1M	↑ 4.66%

	Q1 FY24	Q/Q Change
Profit	$41.0M	↑ 56.95%

	Q2 FY24	Q/Q Change
Profit	$24.7M	↓ 39.86%

	Q3 FY24	Q/Q Change
Profit	$33.4M	↑ 35.59%

	FY18	Y/Y Change
Operating Cash Flow	$-75.5M	↓ 144.33%
Investing Cash Flow	$5.9M	↓ 104.89%
Financing Cash Flow	$139.6M	↑ 486.75%

	FY19	Y/Y Change
Operating Cash Flow	$-140.5M	↑ 86.01%
Investing Cash Flow	$79.7M	↑ 1244.94%
Financing Cash Flow	$1.6M	↓ 98.83%

	FY20	Y/Y Change
Operating Cash Flow	$5.3M	↓ 103.74%
Investing Cash Flow	$-18.7M	↓ 123.49%
Financing Cash Flow	$16.9M	↑ 938.29%

	FY21	Y/Y Change
Operating Cash Flow	$-119.0M	↓ 2363.38%
Investing Cash Flow	$22.5M	↓ 220.15%
Financing Cash Flow	$110.2M	↑ 552.42%

	FY22	Y/Y Change
Operating Cash Flow	$-110.8M	↓ 6.93%
Investing Cash Flow	$22.5M	↑ 0.0%
Financing Cash Flow	$648.0K	↓ 99.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-25.2M	↓ 369.31%
Investing Cash Flow	$26.0M	↓ 117.76%
Financing Cash Flow	$317.0K	↑ 0.0%

Cytomx Therapeutics Technicals Summary

Sell

Neutral

Buy

Cytomx Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cytomx Therapeutics (CTMX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytomx Therapeutics Inc	-26.31%	-27.58%	-42.46%	-80.82%	-87.55%
Biontech Se	-0.32%	51.19%	24.81%	-30.66%	288.02%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.55%	-28.89%	7.15%	74.63%
Vertex Pharmaceuticals Incorporated	16.87%	0.96%	13.03%	93.36%	95.94%
Alnylam Pharmaceuticals, Inc.	17.76%	5.53%	59.46%	84.7%	118.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytomx Therapeutics Inc	5.31	5.31	-1.8	0.03	-54.75	0.02	NA	-0.3
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytomx Therapeutics Inc	Hold	$66.5M	-87.55%	5.31	10.92%
Biontech Se	Buy	$29.7B	288.02%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	74.63%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	95.94%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	118.8%	NA	-15.86%

About Cytomx Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Organization	Cytomx Therapeutics
Employees	120
CEO	Dr. Sean A. McCarthy DPHIL
Industry	Health Technology

Management People of Cytomx Therapeutics

Name	Title
Dr. Sean A. McCarthy DPHIL	Chairman & CEO
Dr. Marcia P. Belvin Ph.D.	Senior VP & Chief Scientific Officer
Mr. Jeffrey Landau B.S., M.B.A.	Senior VP, Head of Strategy & Chief Business Officer
Mr. Christopher W. Ogden	Chief Financial Officer
Mr. Lloyd A. Rowland Jr., J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary
Ms. Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer
Ms. Leslie Robbins	Senior Vice President of Intellectual Property
Dr. Yu-Waye Chu M.D.	Chief Medical Officer
Ms. Dawn Benson	Senior Vice President of Quality & Product Manufacturing
Dr. Hoyoung Huh M.D., Ph.D.	Special Advisor to Chief Executive Officer

Important FAQs about investing in CTMX Stock from India :

What is Cytomx Therapeutics share price today?

Cytomx Therapeutics share price today stands at $0.86, Open: $0.85 ; Previous Close: $0.84 ; High: $0.88 ; Low: $0.83 ; 52 Week High: $5.85 ; 52 Week Low: $0.79.

The stock opens at $0.85, after a previous close of $0.84. The stock reached a daily high of $0.88 and a low of $0.83, with a 52-week high of $5.85 and a 52-week low of $0.79.

Can Indians buy Cytomx Therapeutics shares?

Yes, Indians can invest in the Cytomx Therapeutics (CTMX) from India.

With INDmoney, you can buy Cytomx Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cytomx Therapeutics at zero transaction cost.

How can I buy Cytomx Therapeutics shares from India?

It is very easy to buy Cytomx Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cytomx Therapeutics (CTMX) be purchased?

Yes, you can buy fractional shares of Cytomx Therapeutics with INDmoney app.

What are the documents required to start investing in Cytomx Therapeutics stocks?

To start investing in Cytomx Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.